{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:19:29Z","timestamp":1790651969031,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Research on the relationship between mild COVID-19 and the subsequent development of isolated optic neuritis (ON) with antibodies specific to myelin oligodendrocyte glycoprotein (MOG-ON) and aquaporin 4 (AQP4-ON) is limited, particularly case\u2013control studies that directly compare these conditions within the same affected population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis of initial MOG-ON and AQP4-ON cases during the COVID-19 peak and subsequent months. Patients were classified as possible COVID-19 related ON (PCRON) or non-COVID-19 related ON (NCRON). The study compared epidemiology, comorbidities, and clinical features between these groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with MOG-ON tended to develop ON symptoms closer in time to a mild COVID-19 infection compared to those with AQP4-ON (6.87\u2009\u00b1\u20096.25\u2009weeks vs. 11.06\u2009\u00b1\u20095.84\u2009weeks; <jats:italic>p<\/jats:italic>\u2009=\u20090.038), a significantly higher proportion of patients with MON-ON developing symptoms within 6\u2009weeks after COVID-19 compared to those with AQP4-ON (15\/23 [65.2%] vs. 5\/17 [29.4%]; <jats:italic>p<\/jats:italic>\u2009=\u20090.025). Comparing MOG-ON and AQP4-ON patients, MOG-ON patients were more likely to have a recent infection before ON onset (73.1% vs. 30%; <jats:italic>p<\/jats:italic>\u2009=\u20090.007) and had better peak and post-treatment visual acuity (<jats:italic>p<\/jats:italic>\u2009=\u20090.01; <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). In contrast, AQP4-ON patients frequently showed comorbid connective tissue diseases (30.0% vs. 0%, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) and antinuclear antibody abnormalities (40.0% vs. 7.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.012). Among MOG-ON patients, PCRON had increased rates of atherosclerotic vascular diseases (AVDs) (53.3% vs. 9.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.036), phospholipid antibody abnormalities (60.0% vs. 18.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.04), and bilateral visual impairment (66.7% vs. 9.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.005). Multivariate analysis pinpointed AVDs (OR\u2009=\u200915.21, <jats:italic>p<\/jats:italic>\u2009=\u20090.043) and bilateral involvement (OR\u2009=\u200925.15, <jats:italic>p<\/jats:italic>\u2009=\u20090.015) as independent factors related to COVID-19 associated MOG-ON, with both being good discriminators for PCRON (AUC\u2009=\u20090.879). No differences were found between the PCRON and NCRON groups in AQP4-ON patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Mild COVID-19 is more likely associated with MOG-ON than AQP4-ON. MOG-ON that develops within 6\u2009weeks following a COVID-19 infection may be associated with the COVID-19 infection. AVDs may have a synergistic effect on MOG-ON in patients with COVID-19, which warrants further investigation. COVID-19 related MOG-ON often affects both eyes, and acute visual function damage can be severe, but generally has a good prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1416493","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T04:42:15Z","timestamp":1719376935000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A comparative study on anti-MOG and anti-AQP4 associated optic neuritis following mild COVID-19: insights from a Chinese single-center experience"],"prefix":"10.3389","volume":"15","author":[{"given":"Liang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.46234\/ccdcw2023.070","article-title":"Effectiveness of COVID-19 vaccination against SARS-CoV-2 omicron variant infection and symptoms \u2013 China, December 2022-February 2023","volume":"5","author":"Fu","year":"2023","journal-title":"China CDC Wkly"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S1474-4422(20)30221-0","article-title":"Neurological associations of COVID-19","volume":"19","author":"Ellul","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jfo.2022.09.005","article-title":"Optic neuritis after COVID-19 infection: a case report","volume":"46","author":"Duran","year":"2023","journal-title":"J Fr Ophtalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2324709620976018","DOI":"10.1177\/2324709620976018","article-title":"COVID-19-induced acute bilateral optic neuritis","volume":"8","author":"Sawalha","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e001336","DOI":"10.1136\/bmjophth-2023-001336","article-title":"Systematic review exploring the clinical features of optic neuritis after SARS-CoV infection and vaccination","volume":"8","author":"Georganta","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"101491","DOI":"10.1016\/j.ajoc.2022.101491","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis with COVID-19 infection: a case report and literature review","volume":"26","author":"Assavapongpaiboon","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1097\/WNO.0000000000001347","article-title":"Antiaquaporin 4-related optic neuritis and myelitis post-COVID-19 infection","volume":"42","author":"Kivanany","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2169\/internalmedicine.8709-21","article-title":"SARS-CoV-2-related myelin oligodendrocyte glycoprotein antibody-associated disease: a case report and literature review","volume":"61","author":"Ide","year":"2022","journal-title":"Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"578011","DOI":"10.1016\/j.jneuroim.2022.578011","article-title":"Atypical myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and acute demyelinating polyneuropathy after SARS-CoV-2 infection: case report and literature review","volume":"375","author":"Bosello","year":"2023","journal-title":"J Neuroimmunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/25158414231199541","article-title":"COVID-19 \u2013 a potential trigger for MOGAD-associated optic neuritis: a case report and literature review","volume":"15","author":"Bhardwaj","year":"2023","journal-title":"Ther Adv Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"103697","DOI":"10.1016\/j.msard.2022.103697","article-title":"Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): a case report-based systematic review","volume":"60","author":"Mirmosayyeb","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1177\/1352458520949988","article-title":"COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: cause or coincidence?","volume":"27","author":"Corr\u00eaa","year":"2021","journal-title":"Mult Scler"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"577994","DOI":"10.1016\/j.jneuroim.2022.577994","article-title":"Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: systematic review","volume":"373","author":"Harahsheh","year":"2022","journal-title":"J Neuroimmunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1296518","DOI":"10.3389\/fimmu.2023.1296518","article-title":"Prevalence of serum MOG antibody and AQP4 antibody in optic neuritis after SARS-CoV-2 infection","volume":"14","author":"Sun","year":"2023","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","article-title":"Diagnosis and classification of optic neuritis","volume":"21","author":"Petzold","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/S2214-109X(20)30425-3","article-title":"Vision loss expert Group of the Global Burden of disease study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the global burden of disease study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jns.2015.09.374","article-title":"Neuromyelitis optica spectrum disorder and varicella-zoster infection","volume":"358","author":"Machado","year":"2015","journal-title":"J Neurol Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jneuroim.2018.02.013","article-title":"Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder","volume":"318","author":"Bo","year":"2018","journal-title":"J Neuroimmunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.msard.2017.07.023","article-title":"A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection","volume":"17","author":"Nakamura","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"103286","DOI":"10.1016\/j.msard.2021.103286","article-title":"Impact of COVID-19 public health measures on myelin oligodendrocyte glycoprotein IgG-associated disorders in children","volume":"56","author":"Kaseka","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1111\/ene.15304","article-title":"Is there a correlation between MOG-associated disorder and SARS-CoV-2 infection","volume":"29","author":"Mariotto","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1212\/CON.0000000000001127","article-title":"Myelin oligodendrocyte glycoprotein-associated disorders","volume":"28","author":"Longbrake","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS CoV-2-specific T cell immunity in cases of COVID- 19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1099758","DOI":"10.3389\/fneur.2023.1099758","article-title":"New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review","volume":"14","author":"Harel","year":"2023","journal-title":"Front Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e1060","DOI":"10.1212\/NXI.0000000000001060","article-title":"Clinical features of COVID-19 on patients with Neuromyelitis Optica Spectrum disorders","volume":"8","author":"Apostolos-Pereira","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1305650","DOI":"10.3389\/fimmu.2023.1305650","article-title":"Causal relationships between susceptibility and severity of COVID-19 and neuromyelitis optica spectrum disorder (NMOSD) in European population: a bidirectional Mendelian randomized study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e8408","DOI":"10.7759\/cureus.8408","article-title":"Coronavirus disease 2019 (COVID-19) infection associated with antiphospholipid antibodies and four-extremity deep vein thrombosis in a previously healthy female","volume":"12","author":"Sung","year":"2020","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1136\/annrheumdis-2020-218009","article-title":"Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19","volume":"79","author":"Vlachoyiannopoulos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/biomedicines7020042","article-title":"Neuromyelitis optica spectrum disorder and anti-MOG syndromes","volume":"7","author":"Lana-Peixoto","year":"2019","journal-title":"Biomedicines"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"102718","DOI":"10.1016\/j.msard.2020.102718","article-title":"Anti-MOG associated disorder\u2013clinical and radiological characteristics compared to AQP4-IgG+ NMOSD\u2013A single-center experience","volume":"48","author":"Rempe","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult Scler"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1416493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T04:42:17Z","timestamp":1719376937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1416493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":35,"alternative-id":["10.3389\/fneur.2024.1416493"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1416493","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"article-number":"1416493"}}